文献速递精神分裂症与精神病性障碍儿童青少年精神

NEURAPRO生物标志物分析:长链ω-3脂肪酸改善超高风险青年6个月和12个月结局

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis.
PubMed 文献 · Biol Psychiatry · 2019-09-18

NEURAPRO是一项在304名精神病超高风险个体中开展的多中心安慰剂对照试验,未显示n-3多不饱和脂肪酸(n-3 PUFAs)优于安慰剂。本生物标志物分析对218名有纵向生物标志物数据的参与者进行分析,发现红细胞n-3指数、EPA和DHA的升高预测两个随访时间点更轻的精神病理学和更好的功能;较高的基线n-3指数及其升高预测6个月和12个月的整体临床改善。

要点

  • 红细胞n-3指数、EPA和DHA升高预测超高风险个体随访时更轻精神病理和更好功能。
  • 较高基线n-3指数及n-3 PUFA升高预测6个月和12个月整体临床改善。
  • n-3 PUFA补充可能对超高风险个体具有治疗效应,支持早期干预。

核心结论

  • 数据提示n-3 PUFAs可在超高风险个体中发挥治疗效应,对早期干预和治疗指南有启示。

研究设计与样本

  • NEURAPRO多中心安慰剂对照试验中n-3 PUFAs(鱼油)研究,共304名精神病超高风险个体。
  • 本分析纳入218名有纵向生物标志物数据的参与者,分析基线及第6个月红细胞n-3 PUFAs与临床结局的关系。

主要发现

  • n-3指数、EPA和DHA的升高预测两个随访时间点更轻的精神病理学和更好的功能。
  • 较高基线n-3指数及n-3指数升高预测第6个月整体临床改善(基线n-3指数:调整OR=1.79,95%CI 1.30-2.48;n-3 PUFA升高:调整OR=1.43,95%CI 1.16-1.76)。
  • 较高基线n-3指数及n-3指数升高预测第12个月整体临床改善(基线n-3指数:调整OR=2.60,95%CI 1.71-3.97;n-3 PUFA升高:调整OR=1.36,95%CI 1.06-1.74)。

临床怎么用

  • n-3 PUFA补充可简便安全地用于从初级保健到专科服务的广泛场景。
  • 生物标志物(红细胞n-3指数、EPA、DHA)可用于评估超高风险个体的治疗反应。

局限性

  • 鱼油随机对照试验方法学存在局限:干预组含测试剂,但所有参与者饮食和身体组织中均存在n-3脂肪。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants. METHODS: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) collected as part of NEURAPRO was conducted on 218 participants with longitudinal biomarker data to determine if n-3 PUFAs measured in erythrocytes at baseline and month 6 predicted clinical outcomes. RESULTS: Increases of the n-3 index, EPA, and DHA predicted less severe psychopathology and better functioning at both follow-up time points. Higher baseline levels and increases of n-3 index also predicted overall clinical improvement at month 6 (n-3 index baseline: adjusted odds ratio [95% confidence interval (CI)] = 1.79 [1.30-2.48]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.43 [1.16-1.76]) and at month 12 (n-3 index baseline: adjusted odds ratio [95% CI] = 2.60 [1.71-3.97]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.36 [1.06-1.74]). CONCLUSIONS: These data suggest that n-3 PUFAs can exert therapeutic effects in ultra-high-risk individuals. This finding has implications for early intervention and treatment guidelines, as n-3 PUFA supplementation can easily and safely be used in a wide variety of settings, from primary care to specialist services.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Amminger GP, Nelson B, Markulev C, et al. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biol Psychiatry. 2019. PMID: 31690495. doi:10.1016/j.biopsych.2019.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。